Sitemap
- The Penn Vasculitis Center: A Leader in Vasculitis
- Meet the Team
- Research
- Patient Care
- Donate
- A Randomized Multicenter Study for Isolated Skin Vasculitis: ARAMIS
- Study of Investigational Drug NS-229 to Treat EGPA
- Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy: OCEAN
- Clinical Transcriptomics in Systemic Vasculitis: CUTIS
- Abatacept in Giant Cell Arteritis: ABAGART
- Nasal Microbiome in ANCA-Associated Vasculitis and Relapsing Polychondritis
- Redefining Autoimmune Diseases Across Rheumatology: RADAR
- VCRC Genetic Repository One-Time DNA Study
- VCRC Longitudinal Study of Central Nervous System Vasculitis: CNSV
- VCRC Longitudinal Study of EGPA
- VCRC Longitudinal Study of Relapsing Polychondritis
- Vascular MRI Evaluation in Giant Cell Arteritis: VEGA
- Vasculitis Sino-Nasal Indicators for Flares: V-SNIFF
- Study of Immunomodulatory Medications for Patients with RP: PROSPECT
- Long-term Safety and Efficacy of Avacopan in Participants with ANCA-Associated Vasculitis
- Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis: ABROGATE
- Long-Term Safety Study of Rituximab in Subjects with GPA and MPA
- Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis: PEXIVAS
- Rituximab Compared with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis: RITAZAREM
- Tocilizumab in Subjects with Giant Cell Arteritis: GiACTA
- The Diagnostic and Classification Criteria for Vasculitis Study: DCVAS
- Mepolizumab Compared with Placebo in Subjects with EGPA Receiving Standard of Care Therapy: MIRRA
- Phase 2 Study of Avacopan for the Treatment of ANCA-Associated Vasculitis: CLASSIC
- Phase 3 Study of Avacopan for the Treatment of ANCA-Associated Vasculitis: ADVOCATE
- Safety and Efficacy of Two Different Dose Regimens of IFX-1 as Add-On to Standard of Care in Subjects with GPA and MPA: IXPLORE
- Randomized, Double-Blind Trial of Abatacept for the Treatment of Giant Cell Arteritis